Ibyiyumvo bifitanye isano: 96.97% （95% CI ： 83.35% ～ 99,99%）
Umwihariko ugereranije: 100.00% （95% CI ： 97.29% ～ 100.00%）
Ukuri: 99,50% （95% CI ： 96,94% ～ 99,99%）
Ibisubizo byihuse muminota 15-30 Byihuta antigen kit AMRDT120
Ikizamini cyihuse cyo kumenya ubuziranenge bwo kutabogama
antibodies kuri SARS-CoV-2 cyangwa inkingo zayo mumaraso yose, serumu, cyangwa plasma.
Ibisobanuro by'ipaki: 40 T / kit, 20 T / kit, 10 T / kit, 1 T / kit.
Ibyiyumvo bifitanye isano: 96.97% （95% CI ： 83.35% ～ 99,99%）
Umwihariko ugereranije: 100.00% （95% CI ： 97.29% ～ 100.00%）
Ukuri: 99,50% （95% CI ： 96,94% ～ 99,99%）
Amapaki yuzuye, hamwe na casssttes yikizamini hamwe na desiccants * 20
Suzuma buffer * 20 vial;
Kujugunywa inshuro imwe * 20;
Lancet * 20
Lodine swab * 20
Amabwiriza yo gukoresha * 1
Ibisubizo byihuse muminota 15-30 Byihuta antigen kit AMRDT120 YAKORESHEJWE
Ikizamini cya SARS-CoV-2 Kutabogama kwa Antibody yihuta (COVID-19 Ab) ni immunoassay yihuta ya chromatografique kugirango hamenyekane ubuziranenge bwa antibodiyite kuri SARS-CoV-2 mumaraso yose, serumu, cyangwa plasma.
Ibisubizo byihuse muminota 15-30 Byihuta antigen kit AMRDT120 PRINCIPLE
SARS-CoV-2 Kutabogama Antibody Yihuta (COVID-19 Ab) ni iyo kumenya antibodiyite kuri SARS-CoV-2 cyangwa inkingo zayo.Ingirabuzimafatizo ya selile angiotensin ihindura enzyme-2 (ACE2) yashyizwe mu karere k'ibizamini hamwe na recombinant reseptor-binding domain (RBD) ihujwe n'ibice byerekana.
Mugihe cyo kwipimisha, niba hari SARS-CoV-2 itabuza antibodiyite murugero, yakwitwara hamwe na poroteyine RBD-agace ka conjugate kandi ntigire icyo ikora hamwe na poroteyine ACE2 yabanje gushyirwaho.Uruvange noneho rwimuka hejuru kuri membrane chromatografique hamwe na capillary action kandi ntabwo byafatwa na antigen yabanje gutwikwa.SARS-CoV-2 Kutabogama Antibody Yihuta (COVID-19 Ab) irimo poroteyine RBD ikozweho.Poroteyine ACE2 yubatswe mu karere k'ibizamini.
